1. Dr. Kubat, could you briefly walk us through the foundational concept of mitochondrial transplantation and how it differs from conventional gene or cell therapy approaches?
Mitochondrial Transfer and Transplantation (MTT) is an emerging technique where healthy mitochondria from cultured cells or tissues are introduced into damaged cells or tissues. Unlike gene or stem cell therapy, MTT enhances ATP production and reduces oxidative stress without altering nuclear DNA. This approach is particularly promising for diseases where mitochondrial dysfunction is central, such as myocardial ischemia, neurodegenerative conditions, and muscular atrophy. In contrast to cell therapies, MTT does not carry the risk of tumorigenicity or immune incompatibility. Furthermore, mitochondrial transplantation is less complex in terms of integration since it involves transient organelle supplementation rather than permanent cellular incorporation.
2. In your current research, what are the key challenges in isolating functional mitochondria while preserving their bioenergetic potential and integrity?
Preserving mitochondrial membrane potential and inner membrane integrity is essential for ensuring their viability and functionality after isolation. Common mechanical and chemical isolation methods often compromise mitochondrial cristae, leading to impaired respiration and diminished ATP output. Our protocol follows the McCully approach, which utilizes tissue dissociation at +4°C, filtration steps to prevent physical stress, and rapid processing to limit oxidative damage. Furthermore, functional validation using ATP assays, JC-1 staining for membrane potential, and spectrophotometric enzyme activity measurements ensure that only intact, bioenergetically active mitochondria are used for transplantation. Such rigorous standards are vital for reproducibility and clinical translatability.
3. Nanocarrier-mediated delivery plays a central role in your work. Can you elaborate on the types of nanocarriers you're experimenting with and their comparative efficacy in mitochondrial delivery?
Although we have yet to apply nanocarriers in in vivo experiments, we are actively engaged in collaborations and literature reviews on this emerging strategy. Nanocarriers—including lipid-based vesicles, polymeric nanoparticles, and ROS-responsive nanomotors—offer unique benefits such as targeted delivery, protection from degradation, and enhanced cellular uptake. In our recent Nature Communications perspective, we highlighted how bioengineered vesicles can encapsulate mitochondria to facilitate their passage through biological barriers like the blood-brain barrier (BBB) or gastrointestinal tract. Comparative data suggest that lipid-based carriers mimic natural extracellular vesicles and exhibit superior biocompatibility, while nanomotors provide propulsion and directional control in vivo, particularly useful in ischemic environments where passive diffusion is insufficient.
4. One of innovative angles is the exploration of intranasal and oral delivery routes. What are the biological and technical considerations when deploying mitochondria through these non-invasive pathways?
Non-invasive mitochondrial delivery methods like intranasal and oral administration present exciting opportunities for clinical application. Intranasal delivery leverages direct pathways to the brain via the olfactory and trigeminal nerves, effectively bypassing the BBB. Technically, this requires mitochondria to be packaged in mucoadhesive carriers that can withstand mucosal clearance and promote endocytosis. In contrast, oral delivery faces more significant challenges such as gastric acidity and enzymatic degradation. To overcome this, mitochondria are encapsulated in pH-responsive capsules containing micromotors and targeting peptides. These smart systems ensure mitochondrial protection during transit, facilitate absorption in the gut, and promote biodistribution to target tissues. These methods have shown promising preclinical outcomes in models of ischemic heart disease and stroke.
5. Given the immunological implications, how do host cells typically respond to exogenous mitochondrial transfer? Are there risks of immunogenicity or rejection, and how do you mitigate them?
Interestingly, exogenous mitochondria are generally well tolerated by host cells. Preclinical studies have shown that both autologous and allogeneic mitochondria fail to elicit significant immune responses. For example, Masuzawa et al. demonstrated that mitochondrial infusion did not elevate pro-inflammatory cytokines such as TNF-α, IL-6, or IL-12. Instead, there was an upregulation of reparative factors like EGF and GRO. Moreover, repeated administration did not lead to sensitization or antibody generation, as confirmed by ELISA and FACS analyses. Even xenogeneic transplantation from human to swine or rabbits has been tolerated for up to 28 days without immune rejection. Delivery routes such as intranasal, intra-arterial, or direct tissue injection did not influence immunogenicity, making MTT a promising universal therapy.
6. Wound healing and skeletal muscle atrophy are two application areas you've emphasized. How does mitochondrial transplantation mechanistically restore function in these specific disease models?
In wound healing models, locally delivered mitochondria increase ATP availability and reduce reactive oxygen species, accelerating the proliferative and remodelling phases. We observed enhanced granulation tissue formation, re-epithelialization, and angiogenesis in chronic pressure ulcer patients following MTT. In skeletal muscle atrophy, particularly in doxorubicin-induced models, mitochondrial supplementation restored enzymatic activity, reduced oxidative damage, and preserved muscle fibre cross-sectional area. Importantly, combining MTT with exercise synergistically activated PGC-1α and mitochondrial biogenesis, further enhancing muscle regeneration. These mechanisms not only restore cellular energetics but also suppress pro-apoptotic signalling and support functional recovery.
7. From a translational perspective, what are the biggest hurdles in moving from bench to bedside for mitochondrial transplantation therapies? Are regulatory frameworks catching up with this innovation?
Despite its promise, MTT faces several translational bottlenecks. First, isolated mitochondria have limited viability, often losing membrane potential within hours. Second, targeted delivery remains inefficient, with only a small fraction reaching the affected site. Third, crossing biological barriers such as the BBB or lysosomal degradation remains unsolved. Additionally, regulatory frameworks are underdeveloped, as mitochondria are not cells yet contain DNA, creating ambiguity. There are also ethical concerns about donor mitochondria, especially in allogeneic or xenogeneic use. Strategies like cryopreservation, encapsulation, and extracellular vesicle coating are being explored to improve viability and targeting. However, standardized GMP-grade production and long-term safety profiling are prerequisites for widespread clinical approval.
8. How does the condition of donor mitochondria - whether autologous, allogenic, or xenogenic - impact therapeutic outcomes, and what are the ethical or sourcing considerations involved?
Autologous mitochondria, derived from the patient’s tissues, remain the gold standard due to their immunocompatibility and ease of sourcing during surgical procedures. Allogeneic mitochondria, although effective in preclinical settings, raise concerns about long-term immunogenicity and require rigorous donor screening. Xenogeneic mitochondria offer scalability but are currently limited to research settings due to ethical and cross-species compatibility issues. Emerging alternatives include iPSC-derived mitochondria, which offer a customizable, ethical, and potentially autologous source. Nonetheless, the lack of regulatory clarity surrounding organelle-based products and bio banking procedures calls for the development of dedicated frameworks addressing sourcing, consent, and donor-recipient compatibility.
9. What makes the central nervous system both a promising and challenging field for mitochondrial transfer?
The central nervous system (CNS) represents a critical target due to its high energy demands and susceptibility to mitochondrial dysfunction. Mitochondrial impairment is implicated in stroke, Parkinson’s disease, and Alzheimer’s disease. However, the BBB severely limits access, and even if mitochondria reach the brain, they must remain viable, avoid lysosomal degradation, and integrate with neuronal networks. Current solutions include intranasal delivery systems and mitochondrial encapsulation using polymeric or vesicular carriers that increase brain penetration and reduce clearance. Additionally, researchers are exploring receptor-mediated endocytosis and fusion protein-guided targeting to enhance CNS delivery and integration.
10. Can you share insights into how your team is quantifying mitochondrial uptake, retention, and bioenergetic recovery post-transfer in preclinical models?
We employ a multi-modal approach. Fluorescent dyes like MitoTracker and genetically encoded mitochondrial reporters enable real-time visualization via confocal microscopy and flow cytometry. Post-transfer, we assess oxygen consumption rate (OCR), extracellular acidification rate (ECAR), and ATP levels to determine bioenergetic function. Histological evaluation, mitochondrial enzyme assays, and quantification of oxidative stress markers further confirm functional integration. In vivo, we correlate these metrics with physiological outcomes, such as wound closure speed, muscle mass restoration, and behavioural performance, depending on the disease model. This integrated analysis ensures a robust assessment of both mitochondrial fate and therapeutic efficacy.
11. What role do interdisciplinary collaborations - between nanotechnology, pharmacology, and mitochondrial biology - play in the success of your ongoing projects?
Interdisciplinary collaboration is foundational to our work. Nanotechnology offers advanced delivery systems—such as nanomotors or liposomal vesicles—that protect mitochondria and facilitate targeted, minimally invasive administration. Pharmacology provides frameworks for optimizing mitochondrial pharmacokinetics, bioavailability, and host response modulation. Mitochondrial biology anchors these strategies with precise knowledge on organelle isolation, validation, and integration. These partnerships, particularly in international consortia, enable us to merge expertise from bioengineering, molecular biology, and clinical science to develop scalable and effective MTT therapies.
12. Looking ahead, what are your predictions for the next five years in mitochondrial medicine, and how close are we to seeing scalable, clinically approved mitochondrial therapies?
Over the next five years, mitochondrial medicine is poised for significant clinical milestones. Autologous or vesicle-assisted mitochondrial therapies may enter early-phase clinical trials in cardiac ischemia, stroke, and neurodegeneration. Standardized isolation protocols, cryopreserved organelle banking, and nano-enabled delivery systems will likely become mainstream. Concurrently, gene-edited or iPSC-derived mitochondria could offer personalized solutions for inherited mitochondrial diseases. Regulatory bodies may begin to establish classifications and guidelines for organelle-based therapeutics, akin to those for cell and gene therapies. Although widespread clinical use may take longer, limited approvals and pilot clinical applications are expected, heralding a new era of precision mitochondrial medicine.
References
- Kubat, G. B. (2023). Mitochondrial transplantation and transfer: the promising method for diseases. Turkish Journal of Biology, 47(5), 301-312.
- Preble, J. M., Pacak, C. A., Kondo, H., MacKay, A. A., Cowan, D. B., & McCully, J. D. (2014). Rapid isolation and purification of mitochondria for transplantation by tissue dissociation and differential filtration. Journal of visualized experiments: JoVE, (91), 51682.
- Wu, Z., Chen, L., Guo, W., Wang, J., Ni, H., Liu, J., Jiang, W., Shen, J., Mao, C., Zhou, M., & Wan, M. (2024). Oral mitochondrial transplantation using nanomotors to treat ischaemic heart disease. Nature nanotechnology, 19(9), 1375–1385. https://doi.org/10.1038/s41565-024-01681-7
- Salman, M., Stayton, A. S., Parveen, K., Parveen, A., Puchowicz, M. A., Parvez, S., Bajwa, A., & Ishrat, T. (2024). Intranasal Delivery of Mitochondria Attenuates Brain Injury by AMPK and SIRT1/PGC-1α Pathways in a Murine Model of Photothrombotic Stroke. Molecular neurobiology, 61(5), 2822–2838. https://doi.org/10.1007/s12035-023-03739-4
- McCully, J. D., Del Nido, P. J., & Emani, S. M. (2023). Mitochondrial transplantation: the advance to therapeutic application and molecular modulation. Frontiers in cardiovascular medicine, 10, 1268814.
- Masuzawa, A., Black, K. M., Pacak, C. A., Ericsson, M., Barnett, R. J., Drumm, C., ... & McCully, J. D. (2013). Transplantation of autologously derived mitochondria protects the heart from ischemia-reperfusion injury. American Journal of Physiology-Heart and Circulatory Physiology, 304(7), H966-H982.
- Ramirez-Barbieri, G., Moskowitzova, K., Shin, B., Blitzer, D., Orfany, A., Guariento, A., ... & McCully, J. D. (2019). Alloreactivity and allorecognition of syngeneic and allogeneic mitochondria. Mitochondrion, 46, 103-115.
- Taner, O. F., Ulger, O., Ersahin, S., Baser, N. T., Genc, O., & Kubat, G. B. (2024). Effects of mitochondrial transplantation on chronic pressure wound healing in a human patient. Cytotherapy, 26(6), 579-585.
- Kubat, G. B., Ulger, O., Atalay, O., Fatsa, T., Turkel, I., Ozerklig, B., ... & Tuncer, M. (2024). The effects of exercise and mitochondrial transplantation alone or in combination against Doxorubicin-induced skeletal muscle atrophy. Journal of Muscle Research and Cell Motility, 45(4), 233-251.
- Kubat, G. B., Picone, P., Tuncay, E., Aryan, L., Girgenti, A., Palumbo, L., ... & Nuzzo, D. (2025). Biotechnological approaches and therapeutic potential of mitochondria transfer and transplantation. Nature Communications, 16(1), 5709.
